Fonquerna Pou; Silvia

Patent Applications and Registrations

Patent applications and USPTO patent grants for Fonquerna Pou; Silvia.The latest application filed is for "aminoindazole derivatives as sodium channel inhibitors".

Company Profile

0.13.12

Fonquerna Pou; Silvia - Barcelona ES
Fonquerna Pou; Silvia - Sant Feliu de Llobregat, Barcelona ES
Fonquerna Pou; Silvia - Sant Feliu de Llobregat ES

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Amino-substituted heterocyclic derivatives as sodium channel inhibitors Grant 10,214,509 - Duffy , et al. Feb	2019-02-26
Aminoindazole derivatives as sodium channel inhibitors Grant 10,173,985 - Sole Feu , et al. J	2019-01-08
Aminoindazole Derivatives As Sodium Channel Inhibitors App 20180244626 - SOLE FEU; Laia ; et al.	2018-08-30
Amino-substituted Heterocyclic Derivatives As Sodium Channel Inhibitors App 20180105509 - DUFFY; James ; et al.	2018-04-19
Cyclohexylamine derivatives having .beta.2 adrenergic antagonist and M3 muscarinic antagonist activities Grant 9,643,961 - Prat Quinones , et al. May 9, 2	2017-05-09
Cyclohexyl and quinuclidinyl carbamate derivatives having .beta.2 adrenergic agonist and M3 muscarinic antagonist activity Grant 9,518,050 - Sole Feu , et al. December 13, 2	2016-12-13
New Cyclohexylamine Derivatives Having 2 Adrenergic Agonist And M3 Muscarinic Antagonist Activities App 20160264557 - PRAT QUINONES; Maria ; et al.	2016-09-15
Cyclohexylamine derivatives having .beta.2 adrenergic agonist and M3 muscarinic antagonist activities Grant 9,315,463 - Prat Quinones , et al. April 19, 2	2016-04-19
New Cyclohexyl And Quinuclidinyl Carbamate Derivatives Having Beta2 Adrenergic Agonist And M3 Muscarinic Antagonist Activity App 20150329535 - SOLE FEU; Laia ; et al.	2015-11-19
New Cyclohexylamine Derivatives Having 2 Adrenergic Agonist And M3 Muscarinic Antagonist Activities App 20130281415 - Prat Quinones; Maria ; et al.	2013-10-24
Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors Grant 8,536,165 - Castro Palomino Laria , et al. September 17, 2	2013-09-17
NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES App 20130053359 - Prat Quinones; Maria ; et al.	2013-02-28
1,2,4-oxadiazole Derivatives And Their Therapeutic Use App 20110311485 - Giulio Matassa; Victor ; et al.	2011-12-22
Imidazopyridine derivatives as A.sub.2B adenosine receptor antagonists Grant 7,855,202 - Vidal Juan , et al. December 21, 2	2010-12-21
Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents Grant 7,622,480 - Fonquerna Pou , et al. November 24, 2	2009-11-24
Indolylpiperidine derivatives as potent antihistaminic and antiallergic agents Grant 7,560,471 - Fonquerna Pou , et al. July 14, 2	2009-07-14
Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists App 20080275038 - Vidal Juan; Bernat ; et al.	2008-11-06
Indolylpiperidine derivatives as antihistaminic and antiallergic agents Grant 7,189,741 - Fonquerna Pou , et al. March 13, 2	2007-03-13
New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents App 20060094879 - Fonquerna Pou; Silvia ; et al.	2006-05-04
Indolylpiperidine derivatives as antihistaminic and antiallergic agents Grant 6,683,096 - Pages Santacana , et al. January 27, 2	2004-01-27
Indolylpiperidine derivatives as antihistaminic and antiallergic agents App 20020147344 - Pages Santacana, Lluis ; et al.	2002-10-10

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.